Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

G Wierda, William; J Kipps, Thomas; Mayer, Jirí; Stilgenbauer, Stephan; D Williams, Cathy; Hellmann, Andrzej; Robak, Tadeusz; R Furman, Richard; Hillmen, Peter; Trneny, Marek; J S Dyer, Martin; Padmanabhan, Swami; Piotrowska, Magdalena; Kozak, Tomas; Chan, Geoffrey; Davis, Randy; Losic, Nedjad; Wilms, Joris; A Russell, Charlotte; Osterborg, Anders; Study Investigators, Hx-CD20-406

doi:10.1200/jco.2009.25.3187

Public

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

Published in Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Apr 1, 2010

NobleIDark:/48914/w1/20260526/3601CD32Record on NobleID

Authors:

William G Wierda

,

Thomas J Kipps

,

Jirí Mayer

Abstract

PURPOSE: New treatments are needed for patients with fludarabine- and alemtuzumab-refractory (FA-ref) chronic lymphocytic leukemia (CLL) or patients with fludarabine-refractory CLL with bulky (> 5 cm) lymphadenopathy (BF-ref) who are less suitable for alemtuzumab treatment; these groups have poor ou...

Discussions